 |
 |
Search | |
Vol.34 No.3 contents | Japanese/English |
 |
Full Text of PDF (224K) Article in Japanese |
Risk of Acute Kidney Injury to Patients on Concomitant Tazobactam/piperacillin and Vancomycin Compared to Those on Meropenem and Vancomycin
Hitomi KAWAMURA1)5), Takuya SAKAMOTO1)5), Toshiya SAITO2)5), Machiko SUWA2)5), Mariko HATTORI2)5), Mikiko KUMAZAWA3)5), Yoko ENDO3)5) and Hirokazu TOJIMA4)5)
1)Department of Pharmacy, Tokyo Rosai Hospital, 2)Department of Clinical Laboratory, Tokyo Rosai Hospital, 3)Department of Nursing, Tokyo Rosai Hospital, 4)Department of Respiratory Medicine, Tokyo Rosai Hospital, 5)Infection Control Team, Tokyo Rosai Hospital
Overseas reports indicate that combination therapy with tazobactam/piperacillin (T/P) and vancomycin (VCM) frequently causes acute kidney injury (AKI). In this study, we retrospectively compared AKI frequency in cases receiving T/P + VCM and those receiving meropenem (MEPM) and VCM, another combination used in our hospital for empiric similar coverage. AKI incidence in the T/P + VCM (Eight of 25 cases; 32.0%) was significantly higher than that in the MEPM + VCM (five of 63 cases; 7.9%). A multivariate analysis identified T/P use as the only independent risk factor for AKI (odds ratio 6.77, 95%CI 1.43-32.09). Kidney function should be monitored carefully when T/P + VCM is used regardless of VCM trough values.
Key words：tazobactam/piperacillin, vancomycin, meropenem, combination therapy, acute kidney injury
e-mail: hitomikawamura1113＠gmail.com
Received: September 26, 2018
Accepted: January 31, 2019
34 (3)：210─213,2019
 |
| Copyright © 2003 Japanese Society for Infection Prevention and Control All rights reserved. |